# Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

> **NCT06564974** · — · RECRUITING · sponsor: **Catalyst Pharmaceuticals, Inc.** · enrollment: 250 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Vamorolone

## Key facts

- **NCT ID:** NCT06564974
- **Lead sponsor:** Catalyst Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2032-02
- **Final completion:** 2032-02
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06564974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06564974, "Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06564974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*